Anacor Pharmaceuticals to Present at Deutsche Bank’s 39th Annual Health Care Conference

  Anacor Pharmaceuticals to Present at Deutsche Bank’s 39th Annual Health Care   Conference  Deutsche Bank 39th Annual Health Care Conference  Business Wire  PALO ALTO, Calif. -- May 1, 2014  Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced today that Paul Berns, the company’s President and Chief Executive Officer, will provide a company overview at Deutsche Bank’s 39th Annual Health Care Conference on Thursday, May 8, 2014 at 10:40 a.m. ET in Boston, Massachusetts. The event will be webcast live and may be accessed under “Events and Presentations” on the Investors page of Anacor’s website at www.anacor.com. A replay will also be available for three months following the presentation.  About Anacor Pharmaceuticals  Anacor is a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. Anacor has discovered eight compounds that are currently in development. Its two lead product candidates are topically administered dermatologic compounds — tavaborole, an antifungal for the treatment of onychomycosis, and AN2728, an anti-inflammatory PDE-4 inhibitor for the treatment of atopic dermatitis and psoriasis. In addition to its two lead programs, Anacor has discovered three other wholly-owned clinical product candidates — AN2718 and AN2898, which are backup compounds to tavaborole and AN2728, respectively, and AN3365, an antibiotic for the treatment of infections caused by Gram-negative bacteria. Anacor has also discovered three other compounds that have been out-licensed for further development — one is licensed to Eli Lilly and Company for the treatment of an animal health indication, the second compound, AN5568, also referred to as SCYX-7158, is licensed to Drugs for Neglected Diseases initiative, or DNDi, for human African trypanosomiasis (HAT, or sleeping sickness) and the third compound is licensed to GlaxoSmithKline, LLC for development in tuberculosis. Anacor also has a pipeline of other internally discovered topical and systemic boron-based compounds in development. For more information, visit http://www.anacor.com.  Contact:  Anacor DeDe Sheel, 650-543-7575 Senior Director, Investor Relations and Corporate Communications  
Press spacebar to pause and continue. Press esc to stop.